S U N D A Y , March 19, 2023
EDUCATIONAL SYMPOSIUM of the AGIHO
(supported by a grant by GILEAD Sciences GmbH)
The Hematology Patient and the ICU
10.00-11.30
Interdisciplinary Educational Symposium
Arbeitsgemeinschaft Infektionen der DGHO (AGIHO)
(Infectious Diseases Working Party of the DGHO)
(Lecture Hall III/IV)
Co-Chairs:
D. Seidel, Cologne, DE
Ch. Rieger, Germering, DE
10.00-10.20
D. Teschner, Würzburg, DE
Current Anti-Infective Prophylaxis- and Therapeutic Strategies after Allogeneic Stem Cell Transplantation"
10.20-10.40
D. Seidel, Cologne, DE
Mucormykosis and Covid-19
10.40-11.00
Ch. Rieger, Germering, DE
Vaccinations in Patients with Hematological Malignancies
11.00-11.20
L. Pagano, Rome, I
Covid-19 and its Impact on Hematological Treatment Strategies
12.00-13.40 MS I:
Basic Biology in AML
Lecture Hall III
(Overflow Rooms: LHs IV+V)
Co-Chairs:
W.E. Fibbe, Leiden, NL
C. Müller-Tidow, Heidelberg, DE
12.00-12.20
Th. Oellerich, Frankfurt, DE
Drivers in AML
12.20-12.40
S. Armstrong, Boston, MA, USA
Targeting the Epigenetic Machinery in AML
12.40-13.00
P. van Galen, Boston, MA, USA
Genomics and Transcriptomics of Leukemia Evolution at
Single Cell Resolution".
13.00-13.20
D. Bonnet, London, UK
Mapping the Leukemia Microenvironment
13.20-13.40
C. Bonifer, Birmingham, UK
Understanding AML Development and Evolution through
Transcriptional Network Analysis
14.15-16.00 MS II:
Clonal Evolution and Leukemic Stem Cells
Lecture Hall III
(Overflow Rooms: LHs IV+V)
Co-Chairs:
K. Rouault-Pierre, London, UK
A. Trumpp, Heidelberg, DE
14.15-14.35
R. Majeti, Stanford, CA, USA
Pre-Leukemic Hematopoietic Stem Cells
14.35-14.55
L. Shlush, Rehovot, IL (tbc)
Origin of Mutations in Myeloid Neoplasia
14.55-15.15
I. Jeremias, Munich, DE
Functional Diversity in Leukemic Stem Cells
15.15-15.35
J. Tyner, Chicago, IL, USA
Functional Genomics to Understand Tumor Intrinsic and
Microenvironmental Mechanisms of Myeloid Leukemia
15.35-15.55
C. Lengerke, Tübingen, DE
Immune Escape in AML Stem Cells
M O N D A Y , March 20, 2023
08:30-09:45
OPENING SESSION – ISALXVIII
08:30-08:45
WELCOME ADDRESS
W. Hiddemann, Munich, DE
Symposium Chairman
Lecture Hall III
(Overflow Rooms: LHs IV+V)
08:45-09:45
THOMAS-BÜCHNER LECTURE
Lecture Hall III
(Overflow Rooms: LHs IV+V)
Introduction
G. Ossenkoppele, Amsterdam, NL
B. Ebert, Boston, MA, USA
Clonal Evolution in AML
10:15-11:55 MS III:
Genetic and Molecular Characterization of AML:
Novel Markers for Diagnosis and Prognosis
Lecture Hall III
(Overflow Rooms: LHs IV+V)
Co-Chairs:
G. Ossenkoppele, Amsterdam, NL
F. Thol, Hannover, DE
10:15-10:35
L. Godley, Chicago, IL, USA
Significance of Preleukemic Clones
10:35-10:55
J.J. Schuringa, Groningen, NL
Dissecting Heterogeneity in AML and the Niche
10:55-11:15
K. Tzelepis, Cambridge, UK
The Role of RNA Modifications in Mye3loid Leukaemogenesis
11:15-11:35
K. Metzeler, Leipzig, DE
Clonal Hematopoiesis after AML Treatment
11:35-11:55
M. Andreeff, Houston, TX, USA
Novel Mitochondrial Targets in AML
14:00-15:40 MS IV:
Novel Approaches and Targeted Therapies in AML
Lecture Hall III
(Overflow Rooms LHs IV+V)
Co-Chairs:
B. Löwenberg, Rotterdam, NL
H. Serve, Frankfurt, DE
14:00-14:20
St. De Botton, Villejuif, F
RARA-positive AML is a Novel Patient Subset with an Actionable Target for Treatment with SY-1425, an Oral, Selective RARα Antagonist
14:20-14:40
M.L. Levis, Baltimore, MD, USA
Targeting FLT3
14:40-15:00
C. DiNardo, Houston, TX, USA
The Utility of BCL2 Inhibition in AML
15:00-15:20
M. Konopleva, Houston, TX, USA
Novel Combination Therapies in AML
15:20-15:40
K. Spiekermann, Munich, DE
Therapy Resistance in AML
16:00-18:00 MS V (a):
ON-SITE Poster Viewing and Discussion Session
(Posters will be presented on the Upper Floor of the symposium venue.
A cheese and wine tasting is organized, where a great variety of Bavarian cheese will be served).
All poster presenters are expected to participate in MS V (a) to allow all participants and members of the jury to talk to the presenters and have a personal scientific exchange about their poster(s).
MS V (b): Additional INTERACTIVE virtual Poster Viewing and Discussion Session for virtual participants
Tuesday, March 21, 2023, between 16:00 and 18:00: for details see page 28 of this program
T U E S D A Y, March 21, 2023
10:50-12:30 MS VII:
Current Therapeutic Strategies in AML and APL
Lecture Hall III
(Overflow Rooms LHs IV+V)
Co-Chairs:
A. Burnett, Isle of Arean, UK
U. Platzbecker, Leipzig, DE
10:50-11:10
K. Döhner, Ulm, DE
Current AMLSG Trials
11:10-11:30
P. Montesinos, Valencia, E
The PETHEMA Experience in APL
11:30-11:50
Ch. Röllig, Dresden, DE
Combining Treatment Optimization with Novel Agents:
The SAL Trial Portfolio
11:50-12:10
G.J. Roboz, New York, NY, USA
Non-Transplant Post-Remission Strategies in AML
12:10-12:30
N.H. Russell, Nottingham, UK
Lessons from MRC Strategies in AML
14:00-15:40 MS VIII:
Relevance of MRD in Acute Leukemias
Lecture Hall III
(Overflow Rooms LHs IV+V)
Co-Chairs:
H. Dombret, Paris, F
C. Baldus, Kiel, DE
14:00-14:20
Ch. Hourigan, Bethesda, MA, USA
Clinical Use of MRD in AML
14:20-14:40
J. Cloos, Amsterdam, NL
Impact of Oligoclonality on Accurate MRD Assessment in AML
14:40-15:00
M. Heuser, Hannover, DE
NGS-Based MRD Measurement in AML
15:00-15:20
A. Venditti, Rome, I
MRD-Guided Therapy Strategies in AML
15:20-15:40
R. Walter, Seattle, WA, USA
Is MRD Monitoring in AML Really Helpful?
16:00-17:25 MS IX:
Festive Award Ceremony and Presentations
Lecture Hall VI
Co-Chairs:
K. Götze, Munich, DE
J.H. Klusmann, Halle, DE
16:00-16:10
Poster Prize Announcement and Presentation of Certificates:
Official Announcement and Presentation of Certificates of the
2 ISALXVIII Poster Prize Winners
16.10-16.20
3 Best of Free Contributions: Announcement of Award
Winners, Presentation of Certificates and Talks:
Official Announcement of this Year's 3 Best of Free
Contributions' Winners followed by a 10 minutes' presentation
16.20-16.30
Best of Free Contributions Talk 1: R. Palmieri, Rome, I, Poster # 46
16.30-16.40
Best of Free Contributions Talk 2: J. Müller, Zurich, CH, Poster # 67
16.40-16:50
Best of Free Contributions Talk 3: T. Stopka, Prague, CZ, Poster # 72
16:50-16:55
José Carreras Leukemia Clinical Research Award 2023 (JCLCRA):
Official Announcement of the JCLCRA 2023 Laureate followed by a 15
minutes' presentation
16:55-17:15
JCLCRA 2023 Laureate Talk
17:15-17:25
Awarding of the José Carreras GPOH Doctoral Scholarship 2023
17:30-18:15 MS V (b):
INTERACTIVE virtual Poster Viewing and
Discussion Session for online participants
Virtual WONDER Rooms
W E D N E S D A Y , March 22, 2023
08:30-10:30 MS X:
Immunotherapy for Acute Leukemias
Lecture Hall III
(Overflow Rooms LHs IV+V)
Co-Chairs:
M. Manz, Zurich, CH
M. von Bergwelt, Munich, DE
08:30-08:50
J. DiPersio, St. Louis, MO, USA
Off-the-Shelf Cellular Therapies for T-Cell Malignancies
08:50-09:10
Ch. Craddock, Birmingham, UK
New Transplant Strategies in AML
09:10-09:30
R. Zeiser, Freiburg, DE
Mechanisms of Relapse after AlloSCT
09:30-09:50
S. Gill, Philadelphia, PA, USA
CAR-T Cells in AML Therapy
09:50-10:10
L. Vago, Milano, I
Immune Escape in AML
10:10-10:30 M. Subklewe, Munich, DE
T-Cell Bi-Specifics in AL
11:00-12:40 MS XI:
Biology and Treatment Strategies of ALL
Lecture Hall III
(Overflow Rooms LHs IV+V)
Co-Chairs:
H. Greinix, Graz, A
D. Hoelzer, Frankfurt, DE
11:00-11:20
N. Gökbuget, Frankfurt, DE
Risk-Adapted Therapy of ALL
11:20-11:40
R. Foa, Rome, I
Chemotheraepy-Free Therapy of ALL
11:40-12:00
A. Fielding, London, UK
NCRI Trials in ALL
12:00-12:20
F. Ravandi, Houston, TX, USA
ALL Approach at MD Anderson in 2022
12:20-12:40
M. Müschen, New Haven, CT, USA
Mechanisms of Central Tolerance as Therapeutic
Targets in B-ALL